Neuphoria Therapeutics (NEUP) Cash from Operations (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Cash from Operations for 4 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Cash from Operations fell 129.42% year-over-year to -$3.4 million in Q1 2026; TTM through Mar 2026 was -$17.2 million, a 2734.23% decrease from a year earlier, with the FY2025 full-year figure at $100000.0, up 100.68% from the prior year.
• Cash from Operations was -$3.4 million for Q1 2026 at Neuphoria Therapeutics, up from -$6.4 million in the prior quarter.
• Over five years, Cash from Operations peaked at $11.5 million in Q1 2025 and troughed at -$6.4 million in Q4 2025.
• A 4-year average of -$2.6 million and a median of -$3.6 million in 2025 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations jumped 447.59% in 2025 and slumped 129.42% in 2026, its largest moves.
• Over 4 years, Cash from Operations stood at -$3.9 million in 2023, then increased by 14.88% to -$3.4 million in 2024, then slumped by 91.49% to -$6.4 million in 2025, then jumped by 47.6% to -$3.4 million in 2026.
• The last three Cash from Operations figures came in at -$3.4 million (Q1 2026), -$6.4 million (Q4 2025), and -$3.8 million (Q3 2025), per Business Quant data.